Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients

Journal of Infectious Diseases

Volumn 186, Issue 10, 2002, Pages 1498-1502

  Stone, Shelley F ^a   Lee, Silvia ^a   Keane, Niamh M ^a   Price, Patricia ^a   French, Martyn A ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD26; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; LIVER; MALE; MIDDLE AGED; SOLUBILITY;

EID: 0037111085     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344892     Document Type: Article

References (18)

1. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-28.
2. Saves M. Raffi F. Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother 2000;44:3451-5.
3. Sulkowski MS. Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
4. Perez-Olmeda M. Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000;14:212.
5. Neau D, Trimoulet P, Winnock M, et al. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load, AIDS 2001;15:1736-8.
6. Matsiota-Bernard P, Vrioni G. Onody C. Bernard L, de Truchis P, Peronne C. Human immunodeficiency virus [HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients, Int J Antimicrob Agents 2001;17:155-7.
7. John M. Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An "immune restoration disease"? AIDS 1998;12;2289-93.
8. Fialaire P, Payan C, Vitour D. et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999;180:574-5.
9. French MA, Lenzo N, John M. et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.
10. Martin-Carbonero L, Nunez M, Rios P, et al. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002;16:1423-5.
11. McCaughan GW, Gorrell MD. Bishop GA, et al. Molecular pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and liver transplant tolerance, Immunol Rev 2000;174:172-91.
12. Schweyer S, Mihm S, Radzun HJ, Hartmann H, Fayazzi A. Liver infiltrating T lymphocytes express interferon γ and inducible nitric oxide synthase in chromic hepatitis C virus infection. Gut 2000;46:255-9.
13. Tai DI, Tsai SL, Chen TC, Lo SK. Chang YH, Liaw YF. Modulation of tumor necrosis factor receptors 1 and 2 in chronic hepatitis B and C: The differences and implications in pathogenesis. J Biomed Sci 2001;8:321-7.
14. Stone SF, Price P, Tay-Kearney M, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002;185:1813-7.
15. Keane NM, Price P. Lee S. Stone SF. French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001;126:111-6.
16. Nunez M. Rios P. Martin-Carbonero L. et al. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquit Immune Defic Syndr 2002;30:65-8.
17. Michelet C. Chapplain JM. Petsaris O, et al. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1-infected patients. AIDS 1999;13:1995-6.
18. Yokozaki S, Takamatsu J. Nakano I, et al. Immunological dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: Influence of antiretroviral therapy. Blood 2000;96:4293-9.